Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) disclosed a share buyback executed on 16 September 2026, purchasing 181,600 H-shares on the Hong Kong Stock Exchange. The transaction was completed at prices ranging from HKD 49.96 to HKD 52.00, with a volume-weighted average cost of HKD 51.39 per share, bringing the aggregate consideration to HKD 9.33 million.

Following the repurchase, the company’s issued share base (excluding treasury shares) decreased to 169.58 million, while treasury shares increased to 0.97 million. The total issued share capital, inclusive of treasury shares, remained unchanged at 170.55 million.

The buyback represents 0.107% of the company’s outstanding shares prior to the transaction. Cumulatively, RIBOLIFE-B has repurchased 972,000 shares since receiving shareholder authorisation on 5 June 2026, utilising 5.70% of its 17.06 million-share mandate. All repurchased shares are being held as treasury stock; none have been cancelled.

In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, which is effective until 16 October 2026.